Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-42396302
- Development stage
- Phase 1
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JNJ-42396302 is an orally administered small molecule inhibitor of phosphodiesterase 10A (PDE10A), developed by Janssen-Cilag (a subsidiary of Johnson & Johnson). It belongs to the class of dialkylarylamines and has been investigated in phase 1 clinical trials for its pharmacokinetics and safety in healthy volunteers. The compound exhibits potent inhibition of PDE10A with nanomolar potency in vitro. Its primary mechanism is the inhibition of PDE10A enzyme activity, which may have implications for central nervous system disorders[1][2][4][6].
- Other names
- Imidazo(1,2-b)pyridazine 3-(6-(2-methoxyethyl)-3-pyridinyl)-2-methyl-8-(4-morpholinyl)
02
Targets
PDE10A (Phosphodiesterase 10A)
Beyond the preview
Go deeper on JNJ-42396302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-42396302.